TAGRISSO (osimertinib)

ORAL ADMINISTRATION

Indications for Prior Authorization:

  • First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
  • Treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy

All of the following must be met as a condition for coverage:

  • Prescribed by or in consultation with an oncologist, AND
  • Chart note documentation confirming one of the following:
    • Metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations, OR
    • Metastatic EGFR T790M mutation-positive NSCLC, whose disease has progressed on or after EGFR TKI therapy

This Medication is Not Approvable for the following condition(s):

  • Any condition not listed above as an approved indication

Dosing:

  • 80 mg once daily until disease progression or unacceptable toxicity
  • Avoid co-administration of strong CYP3A4 inducers
  • If concurrent use with strong CYP3A4 inducers is unavoidable:
    • 160mg daily when co-administering with a strong CYP3A inducer
    • Resume Tagrisso at 80mg 3 weeks after discontinuation of strong CYP3A4 inducer

Approval:

  • One year

 

Last review date: April 16, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone